Literature DB >> 25583136

Primary radiotherapy or postoperative radiotherapy in patients with head and neck cancer: Comparative analysis of inflammation-based prognostic scoring systems.

Edgar Selzer1, Anja Grah, Gregor Heiduschka, Gabriela Kornek, Dietmar Thurnher.   

Abstract

INTRODUCTION: Inflammation-based scoring systems have potential value in evaluating the prognosis of cancer patients; however, detailed comparative analyses in well-characterized head and neck cancer patient collectives are missing.
METHODS: We analyzed overall survival (OS) in locally advanced head and neck cancer patients who were treated with curative intent by primary radiotherapy (RT) alone, by RT in combination with cetuximab (RIT) or with cisplatin (RCHT), and by primary surgery followed by postoperative radiotherapy (PORT). The primary RT collective (N = 170) was analyzed separately from the surgery plus RT group (N = 148). OS was estimated using the Kaplan-Meyer method. Cox proportional-hazard regression models were applied to compare the risk of death among patients stratified according to risk factors and the inflammation-based Glasgow Prognostic Score (GPS), the modified GPS (mGPS), the neutrophil-lymphocyte ratio (NLR), the platelet-lymphocyte ratio (PLR), and the prognostic index (PI).
RESULTS: A prognostic relevance of the scoring systems for OS was observed in the primarily irradiated, but not in the PORT collective. OS was 35.5, 18.8, and 15.4 months, respectively, according to GPS 0, 1, and 2. OS according to mGPS 0-2 was identical. The PLR scoring system was not of prognostic relevance, while OS was 27.3 months in the NLR 0 group and 17.3 months in the NLR 1 group. OS was 35.5 months in PI 0, 16.1 months in PI 1, and 22.6 months in PI 2.
CONCLUSION: GPS/mGPS scoring systems are able to discriminate between three risk groups in primarily, but not postoperatively irradiated locally advanced head and neck cancer patients.

Entities:  

Mesh:

Year:  2015        PMID: 25583136     DOI: 10.1007/s00066-014-0803-1

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  30 in total

1.  Correction: Acute-Phase Proteins and Other Systemic Responses to Inflammation.

Authors: 
Journal:  N Engl J Med       Date:  1999-04-29       Impact factor: 91.245

2.  Pretreatment levels of peripheral neutrophils and lymphocytes as independent prognostic factors in patients with nasopharyngeal carcinoma.

Authors:  Jian-Rong He; Guo-Ping Shen; Ze-Fang Ren; Han Qin; Cui Cui; Ying Zhang; Yi-Xin Zeng; Wei-Hua Jia
Journal:  Head Neck       Date:  2012-02-09       Impact factor: 3.147

Review 3.  The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer.

Authors:  Donald C McMillan
Journal:  Cancer Treat Rev       Date:  2012-09-17       Impact factor: 12.111

4.  Improved survival in HPV/p16-positive oropharyngeal cancer patients treated with postoperative radiotherapy.

Authors:  Gregor Heiduschka; Anja Grah; Felicitas Oberndorfer; Lorenz Kadletz; Gabriela Altorjai; Gabriela Kornek; Fritz Wrba; Dietmar Thurnher; Edgar Selzer
Journal:  Strahlenther Onkol       Date:  2014-09-25       Impact factor: 3.621

5.  Elevated neutrophil to lymphocyte ratio predicts poor prognosis in nasopharyngeal carcinoma.

Authors:  Xin An; Pei-Rong Ding; Feng-Hua Wang; Wen-Qi Jiang; Yu-Hong Li
Journal:  Tumour Biol       Date:  2010-10-30

6.  Refining the role of preoperative C-reactive protein by neutrophil/lymphocyte ratio in oral cavity squamous cell carcinoma.

Authors:  Hsuan-Yeh Fang; Xin Yong Huang; Huei-Tzu Chien; Joseph Tung-Chieh Chang; Chun-Ta Liao; Jung-Ju Huang; Fu-Chan Wei; Hung-Ming Wang; I-How Chen; Chung-Jan Kang; Shiang-Fu Huang
Journal:  Laryngoscope       Date:  2013-04-25       Impact factor: 3.325

7.  The relationship between the presence and site of cancer, an inflammation-based prognostic score and biochemical parameters. Initial results of the Glasgow Inflammation Outcome Study.

Authors:  M J Proctor; D Talwar; S M Balmar; D S J O'Reilly; A K Foulis; P G Horgan; D S Morrison; D C McMillan
Journal:  Br J Cancer       Date:  2010-08-17       Impact factor: 7.640

Review 8.  Inflammation and cancer.

Authors:  Lisa M Coussens; Zena Werb
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

9.  Serum C-reactive protein as a prognostic indicator in patients with oral squamous cell carcinoma.

Authors:  Sunil D Khandavilli; Padraig O Ceallaigh; Christopher J Lloyd; Rhiannon Whitaker
Journal:  Oral Oncol       Date:  2009-06-06       Impact factor: 5.337

10.  Elevated preoperative neutrophil/lymphocyte ratio as a predictor of increased long-term survival in minimal invasive coronary artery bypass surgery compared to sternotomy.

Authors:  Basem Azab; Masood A Shariff; Rana Bachir; John P Nabagiez; Joseph T McGinn
Journal:  J Cardiothorac Surg       Date:  2013-09-27       Impact factor: 1.637

View more
  17 in total

1.  Inflammation-based Prognostic Score as a Prognostic Biomarker in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Treated With Nivolumab Therapy.

Authors:  Mioko Matsuo; Ryuji Yasumatsu; Muneyuki Masuda; Satoshi Toh; Takahiro Wakasaki; Kazuki Hashimoto; Rina Jiromaru; Tomomi Manako; Takashi Nakagawa
Journal:  In Vivo       Date:  2022 Mar-Apr       Impact factor: 2.155

2.  Copper chelation by trientine dihydrochloride inhibits liver RFA-induced inflammatory responses in vivo.

Authors:  Ji-Ming Yin; Li-Bo Sun; Jia-Sheng Zheng; Xin-Xin Wang; De-Xi Chen; Ning Li
Journal:  Inflamm Res       Date:  2016-09-09       Impact factor: 4.575

3.  Pretreatment neutrophil to lymphocyte ratio in determining the prognosis of head and neck cancer: a meta-analysis.

Authors:  Yalian Yu; Hongbo Wang; Aihui Yan; Hailong Wang; Xinyao Li; Jiangtao Liu; Wei Li
Journal:  BMC Cancer       Date:  2018-04-04       Impact factor: 4.430

4.  Prognostic score in patients with recurrent or metastatic carcinoma of the head and neck treated with cetuximab and chemotherapy.

Authors:  Teresa Magnes; Thomas Melchardt; Lukas Weiss; Christof Mittermair; Daniel Neureiter; Eckhard Klieser; Simon Gampenrieder; Gerhard Moser; Alexander Gaggl; Richard Greil; Alexander Egle
Journal:  PLoS One       Date:  2017-07-07       Impact factor: 3.240

5.  T cell abundance in blood predicts acute organ toxicity in chemoradiotherapy for head and neck cancer.

Authors:  L Milena Beschel; Martin Leu; Sybille D Reichardt; Margret Rave-Fränk; Markus A Schirmer; Christine Stadelmann; Martin Canis; Hendrik A Wolff; Holger M Reichardt
Journal:  Oncotarget       Date:  2016-10-04

6.  Sensitivity value of hematological markers in patients receiving chemoradiotherapy for esophageal squamous cell carcinoma.

Authors:  Shan Zhu; Chuan-Wang Miao; Zhong-Tang Wang; Li Peng; Baosheng Li
Journal:  Onco Targets Ther       Date:  2016-10-13       Impact factor: 4.147

7.  Impact of hematological inflammatory markers on clinical outcome in patients with salivary duct carcinoma: a multi-institutional study in Japan.

Authors:  Daisuke Kawakita; Yuichiro Tada; Yorihisa Imanishi; Shintaro Beppu; Kiyoaki Tsukahara; Satoshi Kano; Hiroyuki Ozawa; Kenji Okami; Yuichiro Sato; Akira Shimizu; Yukiko Sato; Chihiro Fushimi; Soichiro Takase; Takuro Okada; Hiroki Sato; Kuninori Otsuka; Yoshihiro Watanabe; Akihiro Sakai; Koji Ebisumoto; Takafumi Togashi; Yushi Ueki; Hisayuki Ota; Tomotaka Shimura; Toyoyuki Hanazawa; Shingo Murakami; Toshitaka Nagao
Journal:  Oncotarget       Date:  2017-01-03

8.  Neutrophil-lymphocyte ratio complements volumetric staging as prognostic factor in patients treated with definitive radiotherapy for oropharyngeal cancer.

Authors:  Cédric Panje; Oliver Riesterer; Christoph Glanzmann; Gabriela Studer
Journal:  BMC Cancer       Date:  2017-09-11       Impact factor: 4.430

9.  Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in intensity modulated radiation therapy for nasopharyngeal carcinoma.

Authors:  Yanming Jiang; Song Qu; Xinbin Pan; Shiting Huang; Xiaodong Zhu
Journal:  Oncotarget       Date:  2018-01-11

10.  Optimal cutoff of pretreatment neutrophil-to-lymphocyte ratio in head and neck cancer patients: a meta-analysis and validation study.

Authors:  Jae-Keun Cho; Myoung Woo Kim; Ick Soo Choi; Uk Yeol Moon; Min-Ji Kim; Insuk Sohn; Seonwoo Kim; Han-Sin Jeong
Journal:  BMC Cancer       Date:  2018-10-11       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.